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Background: A number of Nod-like receptors (NLRs) have been shown to inhibit signal transduction pathways using
luciferase reporter assays (LRAs).
Results:Overexpression of NLRX1 and NLRC3 results in nonspecific post-transcriptional inhibition of LRAs.
Conclusion: LRAs are not a reliable technique to assess the inhibitory function of NLRs.
Significance: The inhibitory role of NLRs on specific signal transduction pathways needs to be reevaluated.
Luciferase reporter assays (LRAs) arewidely used to assess the
activity of specific signal transduction pathways. Although pow-
erful, rapid and convenient, this technique can also generate
artifactual results, as revealed for instance in the case of high
throughput screens of inhibitory molecules. Here we demon-
strate that the previously reported inhibitory effect of the
Nod-like receptor (NLR) protein NLRX1 on NF-B- and type I
interferon-dependent pathways in LRAs was a nonspecific con-
sequence of the overexpression of the NLRX1 leucine-rich
repeat (LRR) domain. By comparing luciferase activity and lucif-
erase gene expression using quantitative PCR from the same
samples, we showed that NLRX1 inhibited LRAs in a post-tran-
scriptional manner. In agreement, NLRX1 also repressed LRAs
if luciferase was expressed under the control of a constitutive
promoter, although the degree of inhibition by NLRX1 seemed
to correlate with the dynamic inducibility of luciferase reporter
constructs. Similarly, we observed that overexpression of
another NLR protein, NLRC3, also resulted in artifactual inhi-
bition of LRAs; thus suggesting that the capacity to inhibit LRAs
at a post-transcriptional level is not unique to NLRX1. Finally,
we demonstrate that host type I interferon response to Sendai
virus infection was normal in NLRX1-silenced human
HEK293T cells. Our results thus highlight the fact that LRAs are
not a reliable technique to assess the inhibitory function of
NLRs, and possibly other overexpressed proteins, on signal
transduction pathways.
Nod-like receptors (NLRs)7 represent an important class of
intracellular pattern recognition molecules (PRMs), which are
implicated in the detection and response to microbe- and dan-
ger-associated molecular patterns (MAMPs and DAMPs),
respectively (1). NLRX1 represents the only NLR family mem-
ber that localizes to the mitochondria (2, 3), and recent work
demonstrated that this protein targets the mitochondrial
matrix where it interacts with the matrix-facing protein
UQCRC2of the respiratory chain complex III (4), therebymod-
ulating the production of mitochondrial reactive oxygen spe-
cies, at least in an overexpression setting (3).
The exact role played byNLRX1 in innate immunity remains
unclear. It was proposed that NLRX1 could inhibit cytosolic
antiviral signaling by interacting with MAVS (2). However,
these observations relied in part on the expression of an N-ter-
minal tagged form of NLRX1, which failed to enter into mito-
chondria, likely because the NLRX1 N-terminal mitochondrial
addressing sequence was masked by the added hemagglutinin
(HA) tag (4).More recently, NLRX1-mediated inhibition of sig-
nal transduction pathwayswas shown to rely on themodulation
of the more upstream signaling molecule TRAF6 rather than
MAVS interaction directly (5, 6). TRAF6 is critical for numer-
ous innate immune pathways, including Toll-like receptor
(TLR)-dependent signaling. In agreement with this, NLRX1
was shown to inhibit TLR4-mediated innate immune response
to lipopolysaccharide (5, 6). It remains unclear how NLRX1,
which is found in the mitochondrial matrix, could inhibit
TRAF6-dependent signaling modules present in the cytosol. It
is conceivable that a pool of NLRX1 could be rerouted to the
cytosol in response to specific signals, although this hypothesis
has not been experimentally demonstrated. Finally, it must be
noted that, using an independently generatedNLRX1-deficient
mouse strain, Tschopp and co-workers (7) did not identify
MAVS-dependent antiviral signaling defects in NLRX1/
mice.
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Luciferase reporter assays (LRAs) have been extensively used
in the field of innate immunity to identify the role of PRMs in
the modulation of specific signal transduction pathways. In
these assays, cells are transfected with plasmids encoding for
luciferase enzymes (most commonly from the firefly (Photinus
pyralys) or from the Sea Pansy (Renilla remiformis)), and lucif-
erase expression is under the regulation of specific promoters,
the activity of which being correlated by measuring, in cell
lysates, light emission following conversion of the substrate by
the luciferase enzyme. In the case of the NLR proteins Nod1
and Nod2, NF-B-responsive luciferase constructs (NF-B
Luc) have been used to demonstrate that these proteins activate
the NF-B pathway and detect bacterial peptidoglycan (8–14).
Remarkably, a number of NLR proteins have been shown instead
todown-regulate signal transductionpathways inLRAs, and these
includeNLRX1(2, 5, 6),NLRC3(15),NLRC5(16, 17),NLRP3(18),
NLRP12/Monarch-1 (19) and NLRP2 (20). At least in the case of
NLRP3, it is clear that the initial function assigned to the protein
(i.e. being a negative regulator ofNF-B-dependent signaling)was
incorrect, sinceNLRP3 isnowknowntoactasacritical activatorof
caspase-1 inflammasomes (21).
In the present study, we aimed to better understand the role
played byNLRX1 in themodulation of host signal transduction
pathways, and used LRAs to do so. We were surprised to note
that NLRX1 seemed to potently inhibit several unrelated path-
ways, and that inhibition was irrespective of whether the pro-
tein targeted the mitochondria or the cytosol. These observa-
tions suggested the existence of nonspecific effects of NLRX1
overexpression on the LRAs. This was confirmed by showing
that overexpression of NLRX1 also inhibited luciferase activity
of the enzyme expressed under a constitutive promoter, sug-
gesting that inhibition was post-transcriptional. Further, by
comparing luciferase activity and luciferase gene expression
using quantitative PCR from the same samples, we unequivo-
cally showed that NLRX1 inhibited luciferase post-transcrip-
tionally. Likewise, we observed similar nonspecific effects on
luciferase assays for NLRC3. Finally, we present evidence that
upon Sendai infection, MAVS-dependent antiviral signaling is
normal in NLRX1-silenced cells, thereby supporting the non-
specific effects of NLRX1 overexpression on LRAs. Our results
highlight the difficulty and the risk of using LRAs to identify
putative negative regulators of signal transduction pathways.
We discuss possible mechanisms that could explain why some
NLR proteins inhibit LRAs nonspecifically, and propose to sys-
tematically use qPCR to measure the expression of the Lucifer-
ase gene along with LRAs, in the case of studies aiming at iden-
tifying the potential inhibitory role of LRR-containing and
possibly other overexpressed proteins.
EXPERIMENTAL PROCEDURES
Cell Culture—In LRA experiments, the epithelial cell line,
HEK293T, was used as it offers optimal transfection efficiency
and luciferase expression. Cells were maintained in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 5% fetal
bovine serum (FBS) and penicillin-streptomycin.
Luciferase Transfection and Assay—Luciferase vectors were
co-transfected with a -galactosidase (pCMV-gal, Clontech)
vector for normalization of transfection efficiency. Cells were
seeded in 24-well tissue culture plates the day before to reach a
confluency of at least 60%. Transfection mixes of the two vec-
tors and other co-transfected vectors were normalized to con-
tain the same amount of DNAper well using an empty pcDNA3
expression vector with 300 ng DNA being the minimum for
good transfection efficiency. The transfection reagent, poly-
ethyleneimine, was added to the transfectionmix in the ratio of
3 l per 1 g of DNA and the mix was incubated at room
temperature for 20 min before adding to the cell medium. The
next day, the medium was aspirated and 100 l of lysis buffer
was added (freshly added 1mMDTT, 25mMTris, pH 8.0, 8 mM
MgCl2, 1% Triton X-100, 15% glycerol, water). The plate was
kept at 4 °C for subsequent analysis or20 °C for storage.
For analysis, 10l from eachwell was transferred to a 96-well
white wall plate. Reading buffer was prepared (lysis buffer 1
mM ATP, firefly luciferin). Reading was done using with auto-
mated injection in a Victor3 1420 multilabel counter (Perkin
Elmer) set to measure 0.1s after injection of 100 l of reading
buffer on the sample. In a separate clear wall plate, the -gal
assay was done by first adding 10 l of the lysate to a 96-well
clear bottom plate. 100 l of development buffer was added
(fresh development buffer is stock solution:dilution buffer 
1:9; dilution buffer: 0.06 M Na2HPO4, 0.04 M NaH2PO4, 0.01 M
KCl, 1 mM M MgSO4, pH 7; stock solution: 0.4% ONPG in
dilution buffer,20 °C storage). The mixture was incubated at
37 °C for 10 min or until yellow color appears. The absorbance
wasmeasured at 405 nmusing the Victor3 1420. Luminescence
data were then normalized with -gal absorbance readings for
data analysis purposes.
Luciferase and Other Expression Vectors—The expression
vectors usedwere from the following sources: IgLuc (Dr. Luke
O’Neill, Trinity College, Ireland), ISRE Luc (Dr Kate Fitzgerald,
University of Massachusetts), p53 Luc (Dr. Michael Ohh, Uni-
versity of Toronto, Canada), IFN-Luc reporter plasmid (from
K. Fitzgerald, UMass), pGL3 control (m7G-FF luc, Promega),
pRL-TK (m7G-R luc, Promega), HCV IRES FF Luc (Dr. Jerry
Pelletier, McGill, Canada), bicistronic R-luc-IRES-FF Luc (Dr.
Jerry Pelletier, McGill, Canada), MyD88 (Dr. Fabio Martinon,
UNIL, Lausanne),MAVS (Dr.Kate Fitzgerald,University ofMas-
sachusetts), p53 (Dr. Michael Ohh, University of Toronto, Can-
ada). NLRX1 constructs (NLRX1 FL, N-ter NLRX1, N-ter
NLRX1, HA-NLRX1) have been described previously (3). NLRC3
was cloned from a human cDNA library and inserted into
pEGFP-N1 (Clontech) to generate a GFP-NLRC3 fusion protein.
After cloning, the construct was fully verified by sequencing.
Real Time Quantitative PCR—Following RNA extraction
with Trizol (Invitrogen) or an RNAmini-prep kit, the RNAwas
treated with TURBO DNase (Ambion). The purified RNA was
then reverse transcribed to cDNAusing SuperScript IIIMMLV
reverse transcriptasewith randomhexamer and oligo-dTprim-
ers (Invitrogen). The cDNAwas diluted accordingly and used in
PCR reactions for real time PCR using the Power SYBR Green
2X master mix reagent (ABI). Reactions were performed using
ABI 7900HT real time PCR machine. Results were analyzed
using the 2Ct formula normalizing to the endogenous house-
keeping control, -actin, 18S or cyclophilin. The real time
qPCR primers used are the following: 18S-For: GCAATTATT-
CCCCATGAACG; 18S-Rev: GGGACTTAATCAACGCA-
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AGC; NLRX1-For: AACGGTGCTGGTGACACA; NLRX1-
Rev: GCTCAGCTCATTGAAGTAGA GGT; IFN-For: CAT-
TACCTGAAGGCCAAGGA; IFN-Rev: CAATTGTCCAGT-
CCCAGAGG; LUC-For: GCGCGGAGGAGTTGTGTT (16);
LUC- Rev: TCTGATTTTTCTTGCGTCGAGTT (16).
Western Blot and Cell Fractionation—Cell lysates or protein
samples in SDSLaemmli blue solutionwere analyzedwith SDS-
PAGE. The gels were then transferred onto PVDF membranes
using a semi-dry transfer apparatus and membranes were
blocked with 5% skim milk in TRIS-buffered saline-Tween
(TBS/T: 25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 0.1% Tween
20). Primary antibodies were diluted in TBS/T and incubated
with the membrane in rolling or shaking conditions. Mem-
branes were washed in TBS/T for 1 h and then incubated in
diluted secondary antibody. After washing once more, the
membranes were incubated with chemiluminescence reagents
(Millipore) according to manufacturer’s protocol and exposed
to radiographic film. Fractionation of cell lysates into cytosolic
and heavy membrane fractions was previously described (4).
Antibodies used included mouse mAb against FLAG (clone
M2, Sigma; 1/2000 dilution) and AIF (clone E1, Santa Cruz
Biotechnology; 1/1000).
Generation of Stable HEK293T Cell Lines Expressing siRNA
against Human NLRX1—The pLKO.1 lentiviral knockdown
system (Addgene, Cambridge, MA) was used to generate lenti-
viral shRNA particles against human NLRX1 and a non-target-
ing sequence (scramble). The siRNA sequences (sense strand)
targeting NLRX1 and scramble were as follows. 5-GAGGAG-
GAC TACTACAACGAT-3 (NLRX1) and 5-GTG CAG-
GAGTAGGGCATTTAA-3 (scramble). Oligonucleotides con-
taining these sequences were designed and ligated into the
pLKO.1 vector as previously described (16). shRNA constructs
were fully sequenced. Generation of lentiviral particles was per-
formed in HEK293T cells and was previously described (16).
Briefly, cells were co-transfectedwith the lentiviral shRNA vec-
tor (1 g) and the lentiviral packaging/envelope vectors
psPAX2 (750 ng) and pMD2.G (250 ng). 48 h post-transfection,
cell medium containing the lentiviral particles was collected
and filtered through a 0.45-m syringe to remove any detached
cells. HEK293T cells were transduced with purified lentivirus
for 24 h and fresh medium containing 3 g/ml puromycin
(Sigma) was added to select cells containing shRNAs. Stable
cells expressing shRNAswere selected in puromycin for at least
5 days prior to performing experiments. Knockdown of endog-
enous NLRX1 was verified by Western blot using a polyclonal
NLRX1 antibody (Cederlane, Canada), as well as by qPCR.
Viruses and in Vitro Infections—The Sendai H4 virus strain
(SeV-H4) has been previously described (22, 23). In brief,
HEK293T cells were seeded in 24-well tissue culture plates the
day before and incubated in with virus for 1 h in serum-free
medium.Cells were then rinsedwith 1PBS and freshmedium
containing FBS was added for the duration of the infection.
RESULTS
We sought to determine the effect of NLRX1 overexpression
(either full-length (FL) or deletion constructs, see Fig. 1A) on
the activity of various reporter constructs expressing the firefly
luciferase (FF Luc) under the control of different transcription
factor response elements. HEK293T cells were first transfected
with a NF-B-responsive FF Luc (Ig-Luc) expression vector,
together with a normalization plasmid that expresses -galac-
tosidase constitutively. Of note, all the subsequent LRAs pre-
sented below were also normalized for -galactosidase activity.
While overexpression of TLR adaptorMyD88 potently up-reg-
ulated FF Luc activity, we noticed that overexpression of
increasing amounts of full-length NLRX1-Flag (FL) resulted in
a strong reduction of MyD88-driven FF Luc activity (Fig. 1B).
This result is consistent with reports by other groups who pro-
posed that NLRX1 blocked TLR signaling at the level of TRAF6
(5, 6), which acts downstream ofMyD88 in TLR signaling. Sim-
ilar inhibition was achieved when NLRX1 truncation con-
structs encoding for regions that included the LRR domain
(N-ter or LRR only) were overexpressed (Fig. 1B). This result
was surprising because we previously reported that, while
NLRX1 FL targets the mitochondrial matrix, N-ter or LRR
NLRX1 constructs remain completely cytosolic (3, 4). This sug-
gested that NLRX1-mediated inhibition was either location-
independent (occurring in the mitochondrial matrix or the
cytosol) or that excess overexpression of NLRX1 FL resulted in
the accumulation of a pool of the protein in the cytosol, likely as
a result of the overloading of themitochondrial importmachin-
ery. The latter hypothesis was supported by biochemical frac-
tionation of cytosol versus heavy membranes, which showed
that large overexpression of NLRX1 FL resulted in the cytosolic
accumulation of the protein (Fig. 1C). In further support for
this, overexpression of HA-NLRX1, an epitope-tagged form of
NLRX1 that fails to target mitochondria because of the pres-
ence of an N-terminal HA tag masking the mitochondria local-
ization signal (4), resulted in very potent down-regulation
of MyD88-driven FF Luc activity (Fig. 1D). Interestingly, HA-
NLRX1 seemed to repress luciferase activity more efficiently
than NLRX1-Flag, again suggesting that LRA inhibition by
NLRX1 overexpression was associated with cytosolic accumu-
lation of the protein.
The above results imply that NF-B inhibition in NLRX1-
overexpressing cells was unlikely to be physiologically relevant
because it seemed to occur in a compartment (the cytosol)
where the protein would only accumulate in enforced condi-
tions. In addition, the effect of NLRX1 on NF-B-driven activ-
ity of the FF Luc was unaffected by the mutation of the lysine
172 (NLRX1 K172R) (Fig. 1E), a key amino acid of the P-loop
region of the NACHT domain, which is conserved in all NLR
proteins, and was shown to be critical for the function of all the
NLR proteins in which it has been tested so far (24).
To better understand how NLRX1 overexpression resulted
in apparent down-regulation of NF-B signaling in LRAs, we
decided to characterize if transfection of NLRX1 also affected
the activity of FF Luc expressed under the control of other tran-
scription factor response elements. We observed that NLRX1
FL, N-ter or LRR only, but not N-ter constructs, efficiently
inhibitedMAVS-dependent induction of the luciferase activity
of FF Luc expressed under the control of an interferon-sensitive
response element (ISRE) (Fig. 1F), in agreement with previous
findings (2, 5, 6). NLRX1 also inhibited phorbol 12-myristate
13-acetate (PMA)-dependent induction of the luciferase activ-
ity of FF Luc expressed under the control of an activator protein
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1 (AP-1) response element (Fig. 1G). Because the three signal
transduction pathways tested above (NF-B, type I interferon
and AP-1) are regulated by TRAF6, we aimed to determine if
NLRX1 could also block LRA when luciferase expression was
under the control of very different signaling cascades. We first
noticed that NLRX1 could potently inhibit TNF-induced lucif-
erase expressed under the control of NF-B (data not shown),
although it is well established that TNF signaling to NF-B is
TRAF6-independent. In addition, cells were transfected with
p53-responsive FF Luc expression vector, and as expected,
overexpression of p53 stimulated LRA in these conditions (Fig.
1H).We observed that overexpression of either NLRX1-Flag or
HA-NLRX1 resulted in inhibition of p53-driven induction of
luciferase activity, although we noticed that the inhibitory
FIGURE1.EffectofNLRX1overexpressionon inducible luciferaseexpression reporters.A, schematic representationof theNLRX1deletionconstructsused
in the study: FL, full-length NLRX1 coding sequence; N-ter, deletion of an N-terminal region; N-ter and the LRR refer to the domains by themselves. B, trans-
fection of NLRX1 constructs in increasing amounts (5, 75, 250 ng of plasmid) in the NF-B LRA using co-transfection ofMyD88 to stimulate the reporter. C, cells
transfected to overexpress NLRX1were separated into total cell lysates (Tot.), cytosolic (C), and heavymembrane fractions (HM) andwere analyzed inWestern
blot for NLRX1 and AIF. D, effect of the overexpression of either N-terminal tagged HA-NLRX1 or NLRX1-FLAG in the NF-B LRA stimulated by overexpression
of 100 ng expression vector encodingMyD88. E, wild type and K172R P-loopmutant NLRX1 overexpression in theNF-B LRA. F andG, Similar to theNF-B LRA,
NLRX1constructswere transfected in the (F) ISRE LRAwith co-transfectionofMAVSor (G) AP-1 LRAwithPMAtreatment.H, effect of theoverexpressionof either
N-terminal tagged HA-NLRX1 or NLRX1-FLAG in the p53 LRA stimulated by overexpression of 100 ng expression vector encoding p53. NS, not stimulated.
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effect of NLRX1-Flag on p53-Luc was reproducibly not as pro-
nounced as on the other FF Luc constructs tested above. Once
again, the inhibitory effect was much more dramatic for HA-
NLRX1 than for NLRX1-Flag (Fig. 1H).
These results showed that NLRX1 overexpression inhibited
FF Luc activation irrespective of the transcription factor
response element driving the expression of the luciferase. Inhi-
bition also occurred when NLRX1 was targeted to the cytosolic
compartment, where the protein normally does not reside.
Taken together, these observations thus strongly suggest that
NLRX1-dependent inhibition of LRAs was nonspecific.
In light of the results above, we hypothesized that NLRX1
overexpression might inhibit the luciferase activity of Luc
expressed under the control of a constitutive promoter, which
would strongly support our contention that the inhibition
observed was independent of transcription factor response ele-
ments driving Luc expression. We first noticed that increasing
amounts of transfected NLRX1 FL vector had a minor effect
(20% inhibition at the highest concentration) on the lucifer-
ase activity of FF Luc (Fig. 2A) or Renilla Luc (R Luc) (Fig. 2B)
expressed under the control of a constitutive promoter. Similar
results were obtained with a FF Luc construct expressed under
FIGURE 2. Effect of NLRX1 overexpression on constitutive luciferase expression reporters. A–C, cells were transfected with NLRX1 FL and one of three
constitutive luciferase reporters: (A) firefly luciferase (m7G-FF Luc), (B) Renilla luciferase (m7G-R Luc), and (C) firefly luciferase downstreamof an IRES site derived
from theHepatitis C virus (HCV IRES-FF Luc).D and E, NLRX1was transfectedwithm7G-FF Luc (D) or IRES-FF Luc (E) reporter constructs and co-transfectedwith
either MyD88 or MAVS. F, NLRX1 was transfected together with a constitutive bicistronic reporter that expresses Renilla luciferase with anm7G cap and firefly
luciferasedownstreamof the IRES site (m7G-RLuc-HCV IRES-FF Luc), andco-transfectedwitheitherMyD88orMAVS.Renillaand firefly luciferasedata are shown
on the left and right graphs, respectively. CTR, control.
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the control of a constitutive promoter, but whosemRNA 5 cap
was replaced by an internal ribosome entry site (IRES) from
hepatitis C virus (HCV), thus allowing cap-independent trans-
lation of the FF Luc gene (Fig. 2C). Together, these results sug-
gest that, although there was a reproducible effect of NLRX1
overexpression on luciferase activity in these conditions, the
inhibition capacity was clearly not as robust as when luciferase
expression was driven by inducible factors.
We next reasoned that the contrasting results obtainedwhen
comparing luciferase expression under the control of inducible
or constitutive promoters could be explained by either of the
following: (i) NLRX1 overexpression inhibits LRAs only in
inflammatory (MAVS,MyD88 expression or PMAstimulation)
or stress (p53 expression) conditions; or (ii) NLRX1 overex-
pression blocks luciferase activity only if the enzyme is pro-
duced at a high dynamic rate. We first observed that ectopic
expression of MAVS or MyD88 did not enhance the inhibitory
capacity of NLRX1 over constitutively expressed FF Luc (Fig.
2D), thus suggesting that activation of inflammation/stress
pathways is not a prerequisite for NLRX1-mediated inhibition
of FF Luc activity. We next repeated this experiment with the
HCV IRES FFLuc, whose expression is also under the control of
a constitutive promoter. To our surprise, ectopic expression
of MAVS or MyD88 resulted in a substantial up-regulation of
basal luciferase activity (Fig. 2E), thus suggesting that inflam-
matory pathways might contribute to enhance the translation
of IRES-containingmRNAs, as previously proposed (25). Inter-
estingly, in these circumstances, NLRX1 overexpression
resulted in a substantial inhibition of FF Luc activity (Fig. 2E),
thus suggesting that it is likely the dynamic inducibility of lucif-
erase expression, rather than the action of specific signal trans-
duction pathways, which represents a key factor for NLRX1
inhibitory effect on LRAs. We next observed that the effect of
NLRX1 on Luc-expressing vectors under the control of consti-
tutive promoters was not restricted to constructs carrying an
IRES sequence in their 5-untranslated region. Indeed, NLRX1
efficiently inhibited both R Luc- and FF Luc-dependent lucifer-
ase activities from genes encoded on a bicistronic mRNA
sequence, in which R Luc translation was cap-dependent and R
Lucwas driven by an internal IRES sequence (Fig. 2F). As for the
simple HCV IRES FF Luc construct, luciferase activity was up-
regulated by overexpression of either MAVS or MyD88, and
this affected both R Luc and FF Luc activity, suggesting that the
presence of an IRES sequence likely stabilizes mRNAs in
inflammatory conditions. This shows that the inhibitory effect
of NLRX1 does not require that a given mRNA be translated
under the control of an IRES element.
Together, the results obtained using Luc constructs express-
ing luciferase under the control of constitutive promoters
clearly establish that NLRX1 can inhibit LRAs in a promoter-
independent manner. However, we argue that the inhibitory
effect of NLRX1 is usually more strongly highlighted with Luc
reporter constructs driving luciferase expression in an induci-
ble manner, in response to specific stimuli. The unexpected
capacity of IRES elements to up-regulate luciferase activity in
inflammatory conditions and in a promoter-independent man-
ner allowed us to propose that it is expression inducibility in itself,
FIGURE 3. NLRX1 inhibits LRAs post-transcriptionally. pcDNA3 transfected (negative control) or NLRX1-transfected cells were treated for 4 h with TNF (1
ng/ml) and assayed for (A) NF-B-dependent luciferase activity and (B) luciferase mRNA expression by qPCR. C–E, cell transfected with ISRE Luc expression
vector andMAVS (100 ng), in the presence or absence of overexpressed NLRX1 FL (400 ng) were analyzed in LRA (C) or in qPCR for FF Luc (D) and IFN (E). NS,
not stimulated.
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rather than the activity of any particular pathway, which is critical
for potentiating the inhibitory effect of NLRX1 in LRAs.
The above results, and in particular the differential effect of
NLRX1 on Luc expressed in a cap- versus IRES-dependent
manner, strongly suggested that the effect of NLRX1-depen-
dent inhibition of LRAs was post-transcriptional. To test this
hypothesis directly, we designed a procedure in which lucifer-
ase activity and expression of FF Luc by qPCR were measured
from the same cellular lysates. In this experimental setup,
HEK293T cells were first transfected overnight with an expres-
sion vector encoding for FF Luc under the control of NF-B,
with or without NLRX1-expressing construct. Next, cells were
stimulated for 2.5 or 4 h with TNF, in order to trigger NF-B-
dependent signaling. As expected, overexpression of NLRX1
resulted in a very strong inhibition of luciferase activity, as
determined in LRA (Fig. 3A). However, analysis of the same
samples by qPCR revealed that the reduction of luciferase activ-
ity did not correlate with a decrease in the levels of FF Luc
mRNA levels (Fig. 3B). Similarly, while NLRX1 FL overexpres-
sion efficiently inhibited MAVS-dependent induction of the
luciferase activitywhen FF Lucwas expressed under the control
of ISRE (Fig. 3C), qPCR analysis from the same samples revealed
that NLRX1 expression inhibited neither FF Luc (Fig. 3D) nor
endogenous IFN (Fig. 3E) expression induced by MAVS.
Together, these results provide a direct demonstration that
NLRX1 inhibits LRAs in a post-transcriptional manner, which
likely makes it irrelevant to use this assay to probe the effect of
NLRX1 overexpression on specific signal transduction pathways.
FIGURE 4. NLRC3 also inhibits LRAs post-transcriptionally. A, NLRC3 was transfected by itself in the NF-B LRA in increasing amounts compared with the
effect of transfectingMyD88or treatingwith TNF for 4h.B–G, NLRC3was transfected in the (B) NF-BLRAwithMyD88, (C) ISRE LRAwithMAVS, (D) p53 LRAwith
p53 transfection or etoposide treatment, (E) constitutive m7G-FF Luc assay, (F) constitutive HCV IRES-FF Luc, and (G) constitutive bicistronic m7G-R Luc-HCV
IRES-FF Luc assay.H–I, control () or NLRC3-transfected cells were treated for 4 h with TNF (10 ng/ml) and assayed for (H) NF-B-dependent luciferase activity
and (I) luciferase mRNA expression by qPCR.
NLRX1 and NLRC3 Inhibit Luciferase Assays Nonspecifically
AUGUST 17, 2012•VOLUME 287•NUMBER 34 JOURNAL OF BIOLOGICAL CHEMISTRY 28711
 at U
N
IV
ERSITY
 O
F D
EBRECEN
 on Septem
ber 25, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
We next aimed to determine if post-transcriptional inhibi-
tion of LRAs was specific to NLRX1 or was also observed with
other previously reported inhibitory NLR proteins.We focused
onNLRC3, a poorly characterizedNLR protein that was shown
to suppress T cell functions by inhibiting NF-B- and AP-1-de-
pendent signaling, and this function was mainly inferred by
using LRAs (15).We first observed that NLRC3 overexpression
did not result in activation of NF-B-responsive luciferase
activity (Fig. 4A), and potently inhibited TNF-induced lucifer-
ase activity (Fig. 4B). Similarly, NLRC3 overexpression inhib-
ited luciferase activity triggered by MAVS in cells transfected
with ISRE-responsive FF Luc construct (Fig. 4C) or by etopo-
side in cells transfected with p53-responsive FF Luc construct
(Fig. 4D). As for NLRX1, ectopic expression of NLRC3 resulted
in inhibition of luciferase activity when FF Luc was transcribed
under the control of a constitutive promoter (Fig. 4, E–G), and
the inhibitory effect was even more pronounced in the case of
NLRC3 than it was for NLRX1 overexpression. Finally, we
directly compared luciferase activity and qPCR expression of
the FF Luc gene in cells transfected overnight with an expres-
sion vector encoding for FF Luc under the control of NF-B,
with or without NLRC3-expressing construct, and stimulated
with TNF. In this experimental setting, we demonstrated that
the potent inhibitory effect of NLRC3 on LRAs was, similar to
NLRX1, mediated at a post-transcriptional level. These results
suggest thatNLRX1 andNLRC3 likely inhibit LRAs by a similar
nonspecific post-transcriptional mechanism.
To get insight into the step at which NLRX1 or NLRC3 over-
expression inhibited LRAs post-transcriptionally, FF Luc
expression was next followed by Western blotting. HEK293T
cells were transfected with Ig-Luc plus MyD88, in the pres-
ence or absence of either NLRX1-FLAG or NLRC3-GFP, and
luciferase activitymeasured (Fig. 5A). Interestingly, determina-
tion of FF Luc expression by Western blot on lysates from the
same samples showed a strong correlation between RLAs and
FF Luc protein levels (Fig. 5B), thus demonstrating that
NLRX1- andNLRC3-dependent inhibition of LRAsmust affect
either FF Luc mRNA translation or protein stability, but not
enzymatic inhibition of luciferase activity.
Finally, to complement our NLRX1 overexpression studies
and assess the proposed role of NLRX1 in antiviral signaling,
NLRX1was silenced inHEK239Tcells. A dramatic reduction in
NLRX1 endogenous protein levels was observed in cells
expressing shRNAs targeting NLRX1, as compared with cells
expressing shRNAs targeting a scramble sequence (Fig. 6A). To
model the activation of MAVS-dependent antiviral signaling, a
Sendai virus strain (strainH4) that is a potent activator of inter-
feron- (IFN) production (22, 23) was used to infect scram-
ble- and shNLRX1-expressing HEK293T cells. HEK293T cell
lines expressing shRNAs were transfected with an IFN-Luc
reporter plasmid and infected with Sendai virus for various
times. IFN-Luc activation was comparable in Sendai-infected
scramble and shNLRX1 cell lines (Fig. 6B). To confirm that
IFN mRNA expression was also unaffected in shNLRX1 cell
lines during Sendai virus infection, qPCR was performed. In
line with the luciferase reporter assays, levels of IFN mRNA
were unaffected in NLRX1-knockdown cells compared with
scramble cells (Fig. 6, C and D). Taken together, these results
strongly suggest that NLRX1 does not play a significant role in
MAVS-dependent antiviral signaling in human epithelial cells,
which fully supports the nonspecific effects of NLRX1 overex-
pression on the LRAs.
DISCUSSION
In this study, we present evidence that LRAs are not suitable
for analyzing the potential inhibitory role played by NLRs, and
possibly other proteins displaying a LRR domain, on specific
signal transduction pathways. Our results are not the first to
report nonspecific artifactual data in LRAs, although tracking
these effects in the scientific literature is complicated by the fact
that few studies highlight or aim to investigate the mechanism
underlyingwhat is considered as a technical issue. In the case of
high-throughput screening of compounds with biological
activity using LRAs, the importance of limiting artifactual false-
FIGURE 5.Overexpression of NLRX1 or NLRC3 reduces luciferase protein levels. A and B, HEK293T cells were transfected with Ig-Luc plus MyD88, in the
presence or absence of either NLRX1-FLAG or NLRC3-GFP. Cell lysates were then separated and used for LRA (A) or Western blotting, using antibodies against
FF Luc or tubulin, as a loading control (B). * indicates the presence of a nonspecific band.
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positive results prompted investigators to better understand
the circumstances in which LRAs caused the occurrence of off-
targets effects (26, 27). A first class of molecules that can inter-
fere with LRAs are those inhibiting the enzymatic activity of
luciferase, and these include quinolines, 1,2,4-oxadiazoles, and
benzthiazoles, the latter displaying structural homology with
D-luciferin, the FF Luc substrate (28). Interestingly, nonspecific
accumulation of the enzyme on molecular aggregates has also
been proposed as another possible mechanism of luciferase
activity inhibition, and molecular aggregation seems to repre-
sent an important source of off-target effects in LRA-based
screening of compound libraries (26, 27). The reason why
enzymes such as luciferase accumulate at the surface of molec-
ular aggregates, and how this results in inhibition of the enzy-
matic activity, remain unclear. However, it seems unlikely that
overexpression of NLRX1 LRR domain would inhibit LRAs
through a mechanism involving direct interference with lucif-
erase substrates, because we found that inhibition of LRAs cor-
related with decreased levels of the luciferase protein in cell
lysates (see Fig. 5B). However, it is possible that nonspecific
aggregation of luciferase on overexpressed LRRs from NLRX1
or NLRC3 would result in rapid degradation of the aggregates,
resulting in overall decrease of luciferase protein levels. In sup-
port for this, large overexpression of NLRX1, and in particular
the N-ter construct, leads to the formation of discrete and
bright cytosolic foci in transfected cells (3), which could accu-
mulate protein aggregates. Further work is required to analyze
if protein aggregation accounts for the inhibition of LRAs in
NLRX1- or NLRC3-expressing cells.
In the LRAs presented here, plasmids encoding for luciferase
were systematically co-transfected with a vector expressing
-galactosidase, and all results were normalized for -galacto-
sidase activity, tominimize effects due to transfection efficiency
differences, a procedure that is commonly used in LRAs.While
transfectingNLRX1 orNLRC3 inhibited luciferase activity, it is
intriguing to note that overexpression did not affect the enzy-
matic activity of -galactosidase. The reason for this differen-
tial effect on luciferase and -galactosidase remains unclear
FIGURE 6. Knockdown of NLRX1 does not alter anti-viral signaling during Sendai virus infection. A, human embryonic kidney cells (HEK293T) cells were
transduced with lentiviral particles expressing shRNAs against human NLRX1 or a non-targeting sequence (scramble) and cell lysates were analyzed through
Western blot using anti-NLRX1 antibody. N.S. indicates a nonspecific band (human specific). B, cells as described in A were transfected overnight with an
IFNLuc reporter plasmid and infected with Sendai virus for various time points. Luciferase activity wasmeasured at the time points indicated following virus
infection and overexpression of MAVS was utilized as positive stimulus for IFNLuc activity. C andD, cells described in Awere infected with Sendai virus for 3,
6, or 24 h and total RNAwas extracted. cDNAwas prepared and gene expression levels of humanNLRX1 (C) and IFN (D) weremeasured using qPCR. Each data
point was obtained from an independent experiment for that condition. Statistical analysis was performed using a two-tailed unpaired t test, and conditions
for which p 0.05 are indicated. NLRX1 expression was statistically reduced in cells expressing a shRNA against human NLRX1 at basal conditions (p 0.002)
or when infected with Sendai virus for 3 h (p 0.032), 6 h (p 0.019) and 24 h (p 0.001).
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but, according to the molecular aggregation hypothesis pre-
sented above, the resultsmight be explained by a different affin-
ity of the two enzymes for LRR-induced aggregates. Alterna-
tively, it is possible that differences relate to the fact that, in
these assays, -galactosidase is produced at a constitutive,
poorly dynamic rate, while efficient inhibition of luciferase was
associated with the capacity of the enzyme to be dynamically
regulated. Indeed, by comparing the effects of NLRX1 or
NLRC3 expression on constitutive versus inducible luciferase
constructs we concluded that, although these NLR proteins
blocked LRAs at a post-transcriptional level, the level of inhibi-
tion correlated with the dynamic inducibility of the gene. It is
possible that increasing the rate of luciferase gene transcrip-
tion/translation above a certain threshold favors the accumula-
tion of the enzyme on LRR-induced protein aggregates in the
cell.
The dependence on gene dynamic inducibility for full-blown
inhibitory effects of NLRX1 and NLRC3 in LRAs evoked above
could also possibly explain why these NLR proteins differen-
tially affect LRAs under the control of various transcriptional
response elements, according to the following model (see Fig.
7). In this theoretical model, Luc gene expression can be
induced following threemain kinetics (Fig. 7A): 1) Constitutive,
such as in the case of Luc downstream of a constitutive pro-
moter. 2) Induced-Repressed, in the case of Luc downstream of
a transcriptional response element, such as NF-B. In this case,
the induction of Luc expression is inhibited at late stages
because of the up-regulation of potent NF-B-dependent neg-
ative feedback mechanisms, such as (but not restricted to)
induction of A20 from its endogenous promoter, triggered
simultaneously to the exogenous NF-B-dependent promoter
of the Luc gene. 3) Induced, for Luc gene induced by a specific
transcriptional response element, but refractory to endogenous
negative feedback mechanisms, which could happen if specific
pathways are not, or are only weakly, under the control of neg-
ative feedback loops. Alternatively, this induction profile could
also happen if the Luc gene is controlled by a specific transcrip-
tional response element and that the transcription factor regu-
lating this regulatory element is overexpressed. Indeed, co-ex-
pression of p53 together with p53-Luc would likely bypass
putative endogenous negative feedback mechanisms control-
ling p53 pathway upstream of p53 transcription factor itself.
Similar scenario would likely occur with NF-B p65 overex-
pressed together with Luc controlled by an NF-B-dependent
response element. Considering that NLRX1 or NLRC3 overex-
pressionwould alter the stability of Luc protein or translation of
Luc mRNA, the outcome of the expression of these NLR pro-
teins on Luc levels is expected to be dramatically different
depending on whether Luc gene was expressed under Consti-
tutive, Induced-Repressed or Induced conditions (Fig. 7B). In
particular, down-regulation of Luc protein levels would be
maximal in the Induced-Repressed case, because of the additive
effect of having decreased transcription rate and poor protein
stability or translation rate. We believe that this model offers a
plausible scenario to explain why NLRX1 overexpression was
found to inhibit much better MyD88/Igk-Luc or MAVS/ISRE-
Luc (Induced-Repressed), than p53/p53-Luc (Induced), or
CMV-Luc (Constitutive).
FIGURE 7.Model illustrating thepossible impact ofNLRX1orNLRC3overexpressiononLRAs.A, schematic representation of the threemainmodes of Luc
mRNA induction. In the Constitutive mode, Luc expression is dependent on a constitutive promoter, such as the one of the cytomegalovirus (CMV), which is
commonly used. In the Induced and Induced-Repressed modes, Luc is under the control of inducible response elements (such as NF-B, ISRE, p53, AP-1, etc),
and specific triggers (for instance TNF stimulation or MyD88 overexpression for NF-B pathway, MAVS overexpression for ISRE) can activate both the exoge-
nous Luc gene, as well as endogenous genes involved in negative feedback inhibition (for instance A20 for NF-B signaling). Negative feedback loops
efficiently inhibit thepathways in the Induced-Repressedmode, but not in the Inducedmode.B, theoretical impact of proteindestabilizationonoverall protein
levels, whosegenes are expressedunder theConstitutive, Induced, or Induced-Repressedmodes.Of note, similar theoretical results are expected if theprotein
is unstable of if the mRNA translation is decreased. TF, transcription factor; Luc, Luciferase; Inh, inhibitor.
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Onemight question why activation of the NF-B pathway by
Nod1 and Nod2 can be readily observed using LRA, given the
fact that these NLR proteins also have LRR domains that are
predicted, from our study, to inhibit luciferase activity nonspe-
cifically. It is likely that the very potent capacity of these
molecules to activate NF-B signaling largely overrides the
inhibitory effect on LRAs, resulting in an overall increase in
NF-B-dependent induction of luciferase activity. However, it
is interesting to consider that in this scenario, truncation mol-
ecules of Nod1 or Nod2 that lack the LRR domain would be
predicted to display increased capacity to activate NF-B-
driven luciferase reporter constructs, due to the lack of inhibi-
tory activity of the LRR domain. Indeed, this effect has been
reported, and serves as a basis to formulate the hypothesis that
LRR domains are normally inhibitory for NLR activation, and
that NLR activation requires unfolding of the LRR domain fol-
lowing detection of the PAMP orDAMP (29, 30). In light of our
results, validation of this LRRunfoldingmodel would require to
use alternative techniques, distinct from LRAs, to measure
Nod1 or Nod2 activation.
Besides NLRX1 and NLRC3, NLRC5 is another NLR protein
that was suggested to act as a repressor of multiple signaling
pathways (17), while convergent evidence now suggest that this
protein is a positive regulator of MHC class I expression (31–
36). Using several assays, including LRAs, Cui et al. reported
that NLRC5 overexpression potently inhibited NF-B and
MAVS-dependent signal transduction pathways in human epi-
thelial cell lines (17). Moreover, the inhibition was mediated by
NLRC5 LRR domain (17), a result that, in light of the result
from the present study, could potentially be explained by a
post-transcriptional effect onLRAs. In our hands,we also noted
that overexpression ofNLRC5 repressed pro-inflammatory sig-
nal transduction pathways in LRAs (16). In the case of NF-B-
dependent signaling, we presented a direct comparison of Luc
activity in LRA with Luc expression levels by qPCR, following
the control procedures proposed in the present manuscript
(16). This suggested that overexpression of NLRC5 in human
epithelial cells had an effect, albeit modest, on NF-B signaling
that was not attributable to post-transcriptional inhibition of
LRAs.
Our results strongly suggest that caution should be taken
when studying the potential role of NLR proteins as negative
regulators of signal transduction pathways. In the case of
NLRX1, the previously reported role of the protein as a negative
regulator of NF-B and type I interferon responses relied in
part on LRAs and NLRX1 overexpression (2, 5, 6). Here, we
complement the LRAs studies by silencing NLRX1 in human
epithelial cells and demonstrate that MAVS-dependent antivi-
ral signaling is intact during Sendai virus infection (Fig. 6).
These observations are in agreement with results obtained by
the group of Dr. J. Tschopp that had independently generated
NLRX1-deficient mice, and observed normal MAVS-depen-
dent antiviral responses in NLRX1-deficient cells (mouse
embryonic fibroblasts and bonemarrow-derivedmacrophages)
infected with Sendai virus (7). Therefore, the exact role played
by NLRX1 in innate immunity remains uncertain.
Overall, our results suggest that LRA can generate undesir-
able off-target effects in the case of the overexpression of mol-
ecules containing a LRR domain, which could lead to erroneous
identification of proteins acting as repressors of signal trans-
duction pathways. When using luciferase-expressing con-
structs to monitor the potential inhibitory role of a given pro-
tein on signal transduction pathways, it is advisable to
systematically confirm the results bymeasuring Luciferase gene
expression in qPCR.
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